Carregant...

Abrogating endocrine resistance by targeting ERα and PI3K in breast cancer

Antiestrogen therapies targeting estrogen receptor α (ER) signaling are a mainstay for patients with ER+ breast cancer. While many cancers exhibit resistance to antiestrogen therapies, a large body of clinical and experimental evidence indicates that hyperactivation of the phosphatidylinositol 3-kin...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Fox, Emily M., Arteaga, Carlos L., Miller, Todd W.
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2012
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3472546/
https://ncbi.nlm.nih.gov/pubmed/23087906
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2012.00145
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!